Previous 10 | Next 10 |
- Subgroup analysis of Phase 2 CHARMS study shows rapid resolution of macroscopic hematuria in patients with virus-associated hemorrhagic cystitis treated with Viralym-M - Real world claims data analyses demonstrate worse clinical outcomes, and significantly higher healthcare ...
AlloVir (ALVR): FY GAAP EPS of -$2.59 beats by $1.93.Cash, cash equivalents and short-term investments of $356.32MPress Release For further details see: AlloVir EPS beats by $1.93
- Initiated Phase 3 pivotal clinical trial with Viralym-M, an off-the-shelf multi-virus-specific investigational T-cell therapy, for the treatment of virus-associated hemorrhagic cystitis - Initiated two additional Phase 2 proof-of-concept clinical trials with Viralym-M, inclu...
The US IPO market is expected to remain active in the week ahead with eight IPOs slated to raise $4.6 billion. Street research is expected for Medirom Healthcare Technologies on Monday, 1/25. Lock-up periods will be expiring for eight companies. For further details see: ...
AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster presentation during the Transplantation & Cellular Therapy Meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and ...
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39 th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET. An audio-only webcast of the presentation will be available on January 11 th ...
The FDA has cleared AlloVir's (ALVR) Investigational New Drug ((IND)) application for ALVR106, an allogeneic, off-the-shelf virus-specific T cell therapy designed to target infections and diseases caused by respiratory syncytial virus ((RSV)), influenza, parainfluenza virus ((PIV)), and human...
Proof-of-concept phase 1/2 trial to initiate in 2021 to treat severe respiratory viral infections in patients following hematopoietic stem cell transplantation ALVR106 designed to target devastating diseases caused by four respiratory viruses: respiratory syncytial virus, ...
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf...
- Viralym-M, an allogeneic, off-the-shelf, multi-virus specific T-cell therapy demonstrates 93% of patients achieved a clinical response after treatment of viral infections and disease in patients following allogeneic HSCT - Real-world findings demonstrate significantly hi...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...